Cetylated Fatty Acids (CFAs), such as cetyl myristoleate, have been investigated for their potential benefits in managing symptoms of rheumatoid arthritis (RA). The primary justification for their use is scientific, though the evidence is limited and not robust. CFAs are thought to act by lubricating cell membranes and modulating immune responses, potentially reducing inflammation and improving joint function.

Some small-scale clinical trials and pilot studies have suggested that topical and oral CFAs may help reduce pain and improve mobility in individuals with osteoarthritis and, to a lesser degree, rheumatoid arthritis. For example, a few double-blind, placebo-controlled studies published in peer-reviewed journals have reported modest improvements in pain and function, particularly with topical CFA preparations. However, these studies often have small sample sizes, short durations, and sometimes lack rigorous methodology.

There is currently insufficient high-quality evidence (e.g., large, multicenter randomized controlled trials) specifically supporting the use of CFAs for RA, and most clinical guidelines do not recommend them as standard therapy. The overall quality and quantity of scientific evidence are considered low, with most results being preliminary. Therefore, while there is some scientific basis for their use, the strength of the evidence is weak, and more robust studies are needed to confirm their efficacy and safety in RA management.